The effect of omission of adjuvant radiotherapy after neoadjuvant chemotherapy and breast conserving surgery with a pathologic complete response

被引:5
|
作者
Mandish, Steven F. [1 ]
Gaskins, Jeremy T. [2 ]
Yusuf, Mehran B. [1 ]
Amer, Yomna M. [3 ]
Eldredge-Hindy, Harriet [1 ]
机构
[1] Univ Louisville Hosp, Dept Radiat Oncol, Louisville, KY USA
[2] Univ Louisville, Dept Bioinformat & Biostat, Louisville, KY 40202 USA
[3] Univ Louisville, Sch Med, Louisville, KY 40202 USA
关键词
RADIATION-THERAPY; CANCER; STAGE; IRRADIATION; DISTANCE; OUTCOMES; IMPACT; TRASTUZUMAB; POPULATION; CARCINOMA;
D O I
10.1080/0284186X.2020.1797161
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective(s) Neoadjuvant chemotherapy (NAC) is a standard of care for locally advanced breast cancers. Adjuvant radiotherapy (RT) after NAC is an area of active research. We hypothesize overall survival (OS) is not altered by omitting RT in women with a pathologic complete response (pCR) to NAC after breast conserving survery (BCS). Methods Patients from the National Cancer Database who underwent NAC, BCS, and had a pCR were included. Inflammatory disease, <6 months follow up, and unknown variables were excluded. Descriptive statistics characterized the retained cohort. Logistic regression analyzed the influence of variables on the rate of RT omission. Cox proportional hazard modeling analyzed the influence of prognostic variables on OS. Results Of 5383 women included, 364 (7%) omitted RT. 5-year OS was 94.1% with RT, 93% without. RT omission was most likely in women >70yo (adjusted OR2.4, 95%CI 1.58-3.65,p < .0001;reference 40-49 yo), Hispanic (AOR 1.73, 95%CI 1.19-2.52,p = .0044; reference non-Hispanic), >= 20 miles from treatment facility (20-49 miles; AOR 1.45, 95%CI 1.09-1.93,p = .0109: >50 miles; AOR 2.02, 95%CI 1.42-2.87,p < .0001;reference 0-19 miles), grade 1 (AOR 4.29, 95%CI 2.16-8.51,p < .0001; reference grade 3), and clinical T4 disease (AOR 3.17, 95%CI 1.74-5.79,p = .0002; reference T0/1). Women >= 60yo (60-69: AHR 2.33, 95%CI 1.41-3.83,p = .0009:70+:AHR 2.4, 95%CI 1.24-4.62,p = .0092; reference 40-49) and with N1 and N3 disease (N1: AHR 1.67, 95% CI 2.28-3.24,p = .0034; N3: AHR3.37,95%CI2.01-5.65,p < .0001) showed increased death. Triple-positive (AHR 0.18, 95%CI 0.07-0.43,p = .0002) and HER2+ patients (AHR 0.44, 95%CI 0.30-0.64,p < .0001) had improved OS compared to triple-negative disease. No survival difference was seen with omission of RT (log-rank test:p = .1783; Cox model AHR 1.33, 95%CI 0.76-2.31,p = .3181). Conclusion Women >= 70, of Hispanic origin, living >= 20 miles from treatment facility, and grade 1 disease were more likely to omit RT. HER2+ patients had favorable OS, while older age and N3 disease were negative prognostic factors. Omitting RT after a pCR to NAC and BCS was not found to affect OS.
引用
收藏
页码:1210 / 1217
页数:8
相关论文
共 50 条
  • [31] Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
    Tanioka, M.
    Shimizu, C.
    Yonemori, K.
    Yoshimura, K.
    Tamura, K.
    Kouno, T.
    Ando, M.
    Katsumata, N.
    Tsuda, H.
    Kinoshita, T.
    Fujiwara, Y.
    BRITISH JOURNAL OF CANCER, 2010, 103 (03) : 297 - 302
  • [32] MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer
    Sener, Stephen F.
    Sargent, Rachel E.
    Lee, Connie
    Manchandia, Tejas
    Le-Tran, Vivian
    Olimpiadi, Yuliya
    Zaremba, Nicole
    Alabd, Andrew
    Nelson, Maria
    Lang, Julie E.
    JOURNAL OF SURGICAL ONCOLOGY, 2019, 120 (06) : 903 - 910
  • [33] Do Decreased Breast Microcalcifications After Neoadjuvant Chemotherapy Predict Pathologic Complete Response?
    Fushimi, Atsushi
    Kudo, Rei
    Takeyama, Hiroshi
    CLINICAL BREAST CANCER, 2020, 20 (01) : E82 - E88
  • [34] Omission of Adjuvant Chemotherapy in Rectal Cancer Patients with Pathologic Complete Response: a National Analysis
    Mackenzie C. Morris
    Leah K. Winer
    Tiffany C. Lee
    Shimul A. Shah
    Janice F. Rafferty
    Ian M. Paquette
    Journal of Gastrointestinal Surgery, 2021, 25 : 1857 - 1865
  • [35] Response to Neoadjuvant Chemotherapy as An Indication for Breast-Conserving Surgery
    Wilkinson, A.
    Lee, L.
    Alford, N.
    Okocha, M.
    Gill, J.
    BRITISH JOURNAL OF SURGERY, 2021, 108
  • [36] Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis
    Xuan Li
    Danian Dai
    Bo Chen
    Hailin Tang
    Weidong Wei
    World Journal of Surgical Oncology, 15
  • [37] Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis
    Li, Xuan
    Dai, Danian
    Chen, Bo
    Tang, Hailin
    Wei, Weidong
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2017, 15
  • [38] Breast conserving surgery and locoregional control after neoadjuvant chemotherapy
    Teshome, M.
    Kuerer, H. M.
    EJSO, 2017, 43 (05): : 865 - 874
  • [39] Eliminating Axillary Surgery in Exceptional Responders to Neoadjuvant Chemotherapy with Documented Pathologic Complete Response in the Breast
    Tadros, A.
    Yang, W.
    Krishnamurthy, S.
    Rauch, G.
    Smith, B.
    Valero, V.
    Black, D. M.
    Caudle, A.
    Lucci, A.
    DeSnyder, S.
    Teshome, M.
    Barcenas, C.
    Miggins, M.
    Moseley, T.
    Adrada, B.
    Hwang, R.
    Hunt, K. K.
    Kuerer, H. M.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S11 - S11
  • [40] Role for surgery after complete clinical response to neoadjuvant chemotherapy for breast cancer
    Le Bouëdec, G
    Charrier, S
    Curé, H
    de Latour, MP
    Ferrière, JP
    Chollet, P
    Dauplat, J
    PRESSE MEDICALE, 1999, 28 (39): : 2145 - 2148